Literature DB >> 30560357

A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.

Hyungjin Rhee1, Myeong-Jin Kim2, Young Nyun Park3,4, Chansik An1.   

Abstract

OBJECTIVES: To investigate the clinicopathologic significance of a subclassification of mass-forming intrahepatic cholangiocarcinoma (MF-iCCA) into ductal and parenchymal types based on magnetic resonance imaging (MRI)
METHODS: We enrolled 72 consecutive patients, in whom MF-iCCA was diagnosed on preoperative MRI and surgical resection from January 2000 to March 2013. Two readers independently evaluated MRI findings of adjacent bile duct dilation, periductal tumor spread, and presence of diffuse dilatation or abnormality of the intrahepatic bile duct. MF-iCCAs with none of the aforementioned findings were defined as parenchymal type, and those with one or more findings were defined as ductal type. The enhancement pattern in the arterial phase was also evaluated. Clinical and histopathological findings, as well as post-surgical outcomes, were collected from medical records.
RESULTS: Parenchymal-type MF-iCCA (21/78, 27%) exhibited significantly lower serum carbohydrate antigen 19-9 (12.8 vs. 173.8 U/mL) and carcinoembryonic antigen (1.7 vs. 4.2 ng/mL), more frequent viral hepatitis (43% vs. 18%), less frequent biliary intraepithelial neoplasia (0% vs. 26%), and less frequent perineural invasion (0% vs. 59%) and lymph node metastasis (7% vs. 46%), compared with the ductal type (57/78, 73%) (p < 0.05 for all). Parenchymal-type MF-iCCA showed more frequent arterial hypervascularity (p = 0.001) and better overall survival (p = 0.030) than the ductal type.
CONCLUSION: Subclassification of MF-iCCAs into parenchymal and ductal types may be useful to discriminate clinical and histopathological characteristics and post-surgical outcomes. KEY POINTS: • We propose subclassification of mass-forming intrahepatic cholangiocarcinoma (MF-iCCA) as parenchymal and ductal types, on the basis of magnetic resonance imaging findings of biliary abnormality. • Two types of MF-iCCAs exhibit different clinical and histopathological characteristics and post-surgical outcomes.

Entities:  

Keywords:  Bile duct diseases; Bile ducts; Liver neoplasms; Magnetic resonance imaging; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30560357     DOI: 10.1007/s00330-018-5898-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

Review 1.  Pathology of cholangiocarcinoma.

Authors:  J H Lim; C K Park
Journal:  Abdom Imaging       Date:  2004-06-23

2.  Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.

Authors:  Mina Komuta; Olivier Govaere; Vincent Vandecaveye; Jun Akiba; Werner Van Steenbergen; Chris Verslype; Wim Laleman; Jacques Pirenne; Raymond Aerts; Hirohisa Yano; Frederik Nevens; Baki Topal; Tania Roskams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

3.  Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.

Authors:  Shinichi Aishima; Yousuke Kuroda; Yunosuke Nishihara; Tomohiro Iguchi; Kenichi Taguchi; Akinobu Taketomi; Yoshihiko Maehara; Masazumi Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

4.  Intrahepatic Mass-Forming Cholangiocarcinoma: Relationship Between Computed Tomography Characteristics and Histological Subtypes.

Authors:  Ju Gang Nam; Jeong Min Lee; Ijin Joo; Su Joa Ahn; Jin Young Park; Kyoung Bun Lee; Joon Koo Han
Journal:  J Comput Assist Tomogr       Date:  2018 May/Jun       Impact factor: 1.826

5.  Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings.

Authors:  Nobuhiro Fujita; Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Huanlin Wang; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

6.  Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.

Authors:  Jau-Yu Liau; Jia-Huei Tsai; Ray-Hwang Yuan; Chih-Ning Chang; Hsin-Jung Lee; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2014-01-10       Impact factor: 7.842

Review 7.  Pathologic classification of cholangiocarcinoma: New concepts.

Authors:  Yasuni Nakanuma; Yuko Kakuda
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-02-17       Impact factor: 3.043

Review 8.  Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.

Authors:  Shinichi Aishima; Yoshinao Oda
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-02       Impact factor: 7.027

9.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Authors:  Jesper B Andersen; Bart Spee; Boris R Blechacz; Itzhak Avital; Mina Komuta; Andrew Barbour; Elizabeth A Conner; Matthew C Gillen; Tania Roskams; Lewis R Roberts; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2011-12-13       Impact factor: 22.682

Review 10.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

View more
  8 in total

1.  Differentiation of two subtypes of intrahepatic cholangiocarcinoma: imaging approach.

Authors:  Kengo Yoshimitsu
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

2.  A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma.

Authors:  Gu-Wei Ji; Fei-Peng Zhu; Yu-Dong Zhang; Xi-Sheng Liu; Fei-Yun Wu; Ke Wang; Yong-Xiang Xia; Yao-Dong Zhang; Wang-Jie Jiang; Xiang-Cheng Li; Xue-Hao Wang
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

3.  Combined arterial and delayed enhancement patterns of MRI assist in prognostic prediction for intrahepatic mass-forming cholangiocarcinoma (IMCC).

Authors:  Kai-Pu Jin; Rou-Fan Sheng; Chun Yang; Meng-Su Zeng
Journal:  Abdom Radiol (NY)       Date:  2021-11-25

4.  Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.

Authors:  Sungeun Park; Youngeun Lee; Haeryoung Kim; Mi Hye Yu; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2022-03-30       Impact factor: 12.430

5.  Diffusion-weighted imaging as an imaging biomarker for assessing survival of patients with intrahepatic mass-forming cholangiocarcinoma.

Authors:  Julaluck Promsorn; Kulyada Eurboonyanun; Payia Chadbunchachai; Chaiwat Apivatanasiri; Kosin Wirasorn; Jarin Chindaprasirt; Aumkhae Sookprasert; Mukesh Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2022-06-15

6.  Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.

Authors:  Taek Chung; Hyungjin Rhee; Hyo Sup Shim; Jeong Eun Yoo; Gi Hong Choi; Haeryoung Kim; Young Nyun Park
Journal:  Gut Liver       Date:  2021-11-23       Impact factor: 4.321

7.  Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study.

Authors:  Chansik An; Chang Hee Lee; Jae Ho Byun; Min Hee Lee; Woo Kyoung Jeong; Sang Hyun Choi; Do Young Kim; Young Suk Lim; Young Seok Kim; Ji Hoon Kim; Moon Seok Choi; Myeong Jin Kim
Journal:  Korean J Radiol       Date:  2019-12       Impact factor: 3.500

8.  Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.

Authors:  Jun Zhang; Zhenru Wu; Xin Zhang; Siyun Liu; Jian Zhao; Fang Yuan; Yujun Shi; Bin Song
Journal:  ESMO Open       Date:  2020-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.